The DCGI in its presser on Sunday gave nod to the “emergency restricted” approval for 2 vaccine candidates in India, Bharat Biotech’s Covaxin and Oxford-Astrazeneca’s Covishield. The drug controller mentioned that it’s paying shut consideration to the rising circumstances of UK’s Covid-19 new pressure within the nation and was prioritising its menace whereas conducting scientific trials.
Covid-19 testing on the primary two days of the brand new yr have been under a million. Solely three states reported greater than 1,000 circumstances on Saturday, however Kerala remains to be reporting over 5,000 circumstances. With 5,327 new circumstances on Saturday, Kerala has to this point recorded over 7.71 infections.